120 related articles for article (PubMed ID: 20137927)
1. Novel tetrahydrochinoline derived CETP inhibitors.
Schmeck C; Gielen-Haertwig H; Vakalopoulos A; Bischoff H; Li V; Wirtz G; Weber O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1740-3. PubMed ID: 20137927
[TBL] [Abstract][Full Text] [Related]
2. Chromanol derivatives--a novel class of CETP inhibitors.
Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H
Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein.
Reinhard EJ; Wang JL; Durley RC; Fobian YM; Grapperhaus ML; Hickory BS; Massa MA; Norton MB; Promo MA; Tollefson MB; Vernier WF; Connolly DT; Witherbee BJ; Melton MA; Regina KJ; Smith ME; Sikorski JA
J Med Chem; 2003 May; 46(11):2152-68. PubMed ID: 12747787
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
Kuo GH; Rano T; Pelton P; Demarest KT; Gibbs AC; Murray WV; Damiano BP; Connelly MA
J Med Chem; 2009 Mar; 52(6):1768-72. PubMed ID: 19236017
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
[TBL] [Abstract][Full Text] [Related]
7. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
[TBL] [Abstract][Full Text] [Related]
8. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
[TBL] [Abstract][Full Text] [Related]
9. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047
[TBL] [Abstract][Full Text] [Related]
10. Improved asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol, a potent cholesteryl ester transfer protein inhibitor.
Rano TA; Kuo GH
Org Lett; 2009 Jul; 11(13):2812-5. PubMed ID: 19507869
[TBL] [Abstract][Full Text] [Related]
11. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease.
Sikorski JA
J Med Chem; 2006 Jan; 49(1):1-22. PubMed ID: 16392785
[No Abstract] [Full Text] [Related]
12. Design of a novel class of biphenyl CETP inhibitors.
Lu Z; Napolitano JB; Theberge A; Ali A; Hammond ML; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2010 Dec; 20(24):7469-72. PubMed ID: 21041082
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
[TBL] [Abstract][Full Text] [Related]
14. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V
Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716
[TBL] [Abstract][Full Text] [Related]
15. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
Castilho MS; Guido RV; Andricopulo AD
Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633
[TBL] [Abstract][Full Text] [Related]
16. Refocusing on use of cholesteryl ester transfer protein inhibitors.
Kastelein JJ
Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
[TBL] [Abstract][Full Text] [Related]
17. Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones.
Lohray BB; Bhushan V; Reddy AS; Rao PB; Reddy NJ; Harikishore P; Haritha N; Vikramadityan RK; Chakrabarti R; Rajagopalan R; Katneni K
J Med Chem; 1999 Jul; 42(14):2569-81. PubMed ID: 10411477
[TBL] [Abstract][Full Text] [Related]
18. Torcetrapib for animal and human pharmacokinetic studies: applicability of chiral and achiral methodologies.
Ramesh M; Trivedi RK; Srinivas NR
Bioanalysis; 2009 Jun; 1(3):619-28. PubMed ID: 21083157
[TBL] [Abstract][Full Text] [Related]
19. Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein.
Cunningham D; Lin W; Hoth LR; Danley DE; Ruggeri RB; Geoghegan KF; Chrunyk BA; Boyd JG
Bioconjug Chem; 2008 Aug; 19(8):1604-13. PubMed ID: 18646836
[TBL] [Abstract][Full Text] [Related]
20. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
